1. P-291The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress. (20th June 2018) Authors: Ziranu, P; Demurtas, L; Puzzoni, M; Loupakis, F; Daniele, B; Rimassa, L; Bilancia, D; Lonardi, S; Avallone, A; Pella, N; Ferrari, D; Frassineti, L; Beretta, G; Zaniboni, A; Santoro, A; Zampino, M; Sarobba, M; Zagonel, V; Barni, S; Palmieri, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗